CHRN
ChronoScale Corporation
There isn't enough reported data to score CHRN yet.
MU
Micron Technology, Inc.
MU's fundamentals are strong and it looks cheap: trading at 11x earnings, about half its usual 22x. Analysts expect strong earnings growth.
CHRN Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
CHRN's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
MU Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
MU's revenue, profitability, cash flow and balance sheet are all currently strong.
CHRN PE Valuation
CHRN has no meaningful PE right now: it lost money over the past year.
MU PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 4.6x | $798 | — |
| Cheap | 10x | $777 | -2.7% |
| Current | 11x | $798 | — |
| Fair | 22x | $1,646 | +106% |
| Expensive | 32x | $2,404 | +201% |
Historical ranges are pointers, not guarantees.
MU's PE is in its cheap range at 11x. If earnings grow as analysts expect, today's price would be 4.6x next year's earnings.
CHRN Forward outlook
There aren't enough analyst estimates for CHRN to show an outlook.
MU Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Broad | |
| Moderate |
Analysts expect strong earnings and revenue growth for MU, with profitability improving.
CHRN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q1 2026 | -$6.83 | +$0.40 |
| Q4 2025 | -$6.59 | +$1.84 |
| Q3 2025 | -$5.56 | +$4.19 |
| Q2 2025 | -$6.52 | +$5.33 |
| Q1 2025 | -$7.23 | +$7.32 |
| Q4 2024 | -$8.43 | +$8.07 |
| Q3 2024 | -$9.75 | +$7.05 |
| Q2 2024 | -$11.85 | +$6.30 |
MU has the stronger earnings trend. Trailing diluted EPS is down 194% for CHRN versus MU up 879%.
MU Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $174.95 | +135% |
| Q3 2026 | $74.33 | +879% |
| Q2 2026 | $44.17 | +693% |
| Q1 2026 | $21.18 | +405% |
| Q4 2025 | $10.52 | +201% |
| Q3 2025 | $7.59 | +984% |
| Q2 2025 | $5.57 | +$6.99 |
| Q1 2025 | $4.19 | +$7.64 |
| Q4 2024 | $3.49 | +$9.77 |
MU's earnings per share have climbed steadily: $74.33 over the past year, about 10 times what it earned the year before, and higher year over year for 10 quarters in a row.
CHRN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $41.5M | +881% |
| Q1 2026 | $2.1M | -37% |
| Q4 2025 | $3.1M | -38% |
| Q3 2025 | $4.2M | +2.4% |
| Q2 2025 | $2.1M | -58% |
| Q1 2025 | $3.4M | -10% |
| Q4 2024 | $5.1M | +5% |
| Q3 2024 | $4.1M | -10% |
CHRN's revenue is growing: $41M last quarter, up 1917% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -60% | +133 points |
| Q1 2026 | -262% | -161 points |
| Q4 2025 | -144% | -100 points |
| Q3 2025 | -33% | +31 points |
| Q2 2025 | -193% | -146 points |
| Q1 2025 | -102% | -15 points |
| Q4 2024 | -44% | +27 points |
| Q3 2024 | -64% | -0.3 points |
CHRN's operating margin was −60% last quarter, up 133 points from the same quarter a year ago.
MU Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $54.2B | +379% |
| Q2 2026 | $41.5B | +346% |
| Q1 2026 | $23.9B | +196% |
| Q4 2025 | $13.6B | +57% |
| Q3 2025 | $11.3B | +46% |
| Q2 2025 | $9.3B | +37% |
| Q1 2025 | $8.1B | +38% |
| Q4 2024 | $8.7B | +84% |
MU has the edge over CHRN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 81% | +48 points |
| Q2 2026 | 80% | +57 points |
| Q1 2026 | 68% | +46 points |
| Q4 2025 | 45% | +20 points |
| Q3 2025 | 32% | +13 points |
| Q2 2025 | 23% | +13 points |
| Q1 2025 | 22% | +19 points |
| Q4 2024 | 25% | +49 points |
MU has the edge over CHRN on profitability, with a higher operating margin.
CHRN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $11.6M | +$13.6M |
| Q1 2026 | -$2.1M | -$148K |
| Q4 2025 | -$4.5M | -$3M |
| Q3 2025 | -$2.1M | +$212K |
| Q2 2025 | -$3.5M | -$814K |
| Q1 2025 | -$2M | +$1.5M |
| Q4 2024 | -$1.5M | +$173K |
| Q3 2024 | -$2.3M | +$1.1M |
CHRN's free cash flow has turned positive after six years mostly in the red: $3M over the past year.
MU Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $32.9B | +45543% |
| Q2 2026 | $17.6B | +951% |
| Q1 2026 | $5.5B | +$5.6B |
| Q4 2025 | $3B | +7853% |
| Q3 2025 | $72M | -75% |
| Q2 2025 | $1.7B | +322% |
| Q1 2025 | -$113M | +$52M |
| Q4 2024 | $38M | +$433M |
MU has the edge over CHRN on cash flow, with more consistent year-over-year improvement.
CHRN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3981% | +142M shares |
| 1 year | +8489% | +144M shares |
| 3 years | +16727% | +145M shares |
| 5 years | +34737% | +145M shares |
CHRN has 145M diluted shares, up 8489% from a year ago.
MU Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -2M shares |
| 1 year | +1.6% | +18M shares |
| 3 years | +4.6% | +50M shares |
| 5 years | +0.2% | +2M shares |
| Available history | +1.2% | +14M shares |
MU has the edge over CHRN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | $350M |
| Q4 2025 | $300M |
| Q3 2024 | $300M |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
MU has spent almost nothing on buybacks in the past year.
CHRN Net Leverage
CHRN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
MU Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.3x | Net Cash |
| Q2 2026 | -0.3x | Net Cash |
| Q1 2026 | -0.1x | Net Cash |
| Q4 2025 | 0.1x | Very low |
| Q3 2025 | 0.3x | Very low |
| Q2 2025 | 0.3x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
MU has more cash than debt.
CHRN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.3 | Neutral |
| Stochastic | 8.3 | Oversold |
CHRN's weekly RSI is 37 (neutral) and its Stochastic is 8 (oversold).
MU Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.1 | Neutral |
| Stochastic | 26.9 | Neutral |
MU's weekly RSI is 47 (neutral) and its Stochastic is 27 (neutral).
CHRN PE vs Technology Sector
CHRN has no meaningful PE right now: it lost money over the past year.
MU PE vs Technology Sector
| Metric | MU | Sector median | Relative |
|---|---|---|---|
| PE | 11x | 28x | 61% below |
| PE % | 18 | 35 | 17 pts below |
MU is trading at 11x earnings, a 61% discount to the Technology sector's median of 28x.
CHRN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $15.4 | 30% below |
| 20 week MA | $18.8 | 42% below |
| 50 week MA | $14.5 | 25% below |
| 100 week MA | $10.1 | 7.5% above |
| 200 week MA | $14.9 | 27% below |
CHRN's trend is mixed: it's above one of its five weekly moving averages, and 27% below its 200-week average.
MU Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $914.5 | 13% below |
| 20 week MA | $931.0 | 14% below |
| 50 week MA | $685.9 | 16% above |
| 100 week MA | $405.4 | 97% above |
| 200 week MA | $246.0 | 225% above |
MU has the edge over CHRN on trend strength, trading above more of its moving averages.
CHRN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $78.8 | $104.7 | +33% |
| 2021 | $104.7 | $45.3 | -57% |
| 2022 | $45.3 | $18.6 | -59% |
| 2023 | $18.6 | $37.5 | +102% |
| 2024 | $37.5 | $9.74 | -74% |
| 2025 | $9.74 | $5.56 | -43% |
| 2026 YTD | $5.56 | $10.9 | +95% |
CHRN's yearly returns have swung widely, from +102% in 2023 to −74% in 2024. It's up 95% so far in 2026.
MU Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $54.0 | $70.6 | +31% |
| 2021 | $70.6 | $94.4 | +34% |
| 2022 | $94.4 | $50.2 | -47% |
| 2023 | $50.2 | $85.3 | +70% |
| 2024 | $85.3 | $88.6 | +3.9% |
| 2025 | $88.6 | $284.8 | +221% |
| 2026 YTD | $284.8 | $798.4 | +180% |
MU has the edge over CHRN on returns for 2026, with the stronger performance.